You are here

Article Text

Article menu
Download PDFPDF
New devices and techniques
Review
Catheter design primer for neurointerventionalists
  1. Cem Bilgin1,
  2. Jared Hutar2,
  3. Jiahui Li3,
  4. Oscar Castaño4,5,
  5. Marc Ribo3,6,
  6. David F Kallmes1
  1. 1 Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
  2. 2 Conway Medical, Minneapolis, Minnesota, USA
  3. 3 Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain
  4. 4 Electronics and Biomedical Engineering, University of Barcelona, Barcelona, Catalunya, Spain
  5. 5 Biomaterials for Regenerative Therapies, Institute for Bioengineering in Catalonia, Barcelona, Catalunya, Spain
  6. 6 Stroke Unit, Hospital Vall d'Hebron, Barcelona, Spain
  1. Correspondence to Dr Cem Bilgin, Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA; bilgin.cem{at}mayo.edu

Abstract

Neurovascular catheter technology has rapidly evolved over the past decade. While performance characteristics are well known to the practitioner, the design features of these new-generation catheters and their implications on performance metrics remain a mystery to most clinicians due to the limited number of available resources. This knowledge gap hampers informed device choices and also limits collaboration between clinicians and engineers. To aid fellow neurointerventionalists, in this primer we have summarized the basic concepts of catheter design and construction.

  • Catheter
  • Device
  • Technology

https://doi.org/10.1136/jnis-2022-019567

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Twitter @marcriboj

    • Contributors All authors contributed to the manuscript. CB, JH, JL and DFK were responsible for the conception and design of the work. All authors were involved in drafting the article, critical revision of the article, and final approval of the version to be published.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests DFK received research support from Cerenovus, Insera Therapeutics, Medtronic, Microvention, Balt, Monarch Biosciences, Brainomix, MiVi, Stryker, and royalties from Medtronic, has ownership interests in Nested Knowledge, Superior Medical Experts, Marblehead Medical, Conway Medical, Monarch Biosciences, Piraeus Medical, serves in advisory boards of NoNo Inc. and Vesalio. MR received research support from Medtronic and Balt and served as a consultant to Anaconda Biomed, Medtronic, Cerenovus, Stryker, Philips, Apta Targets, received Honoria from Boehringer Ingelheim, Ischemia View, Balt, and serves on an advisory board of Sensome. OC received research support from, and has ownership interest in Laboratorios ERN S.A. JL received honoria from Medtronic.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.